Staphylococcus sp, antimicrobial treatment and resistance in canine superficial bacterial pyoderma

MENESES, M.L.1,2; MARTIN, P.L.2; MANZUC, P.3; ARAUZ, M.S.2; PARDO, A.G.1

Revista Veterinaria

Publicación oficial de la Facultad de Ciencias Veterinarias de la Universidad Nacional del Nordeste (UNNE)

Lugar: Corrientes; Año: 2018 vol. 29 p. 88 - 92

1668-4834

Meneses, M.L.; Martin, P.L.; Manzuc, P.; Arauz, M.S.; Pardo, A.G.: Staphylococcus sp, antimicrobial treatment and resistance in canine superficial bacterial pyoderma. Rev. vet. 29: 2, 88-92, 2018. In Buenos Aires, Argentina, few studies are available regarding the frequency of the antimicrobial treatment for canine pyoderma and the level of antimicrobial resistance of Staphylococcus sp. The main objectives of this study were to analyze the antimicrobial resistance of Staphylococcus sp and the frequency of antimicrobial treatment of canines with pyoderma and their relapses. A total of 39 canines with clinical diagnosis of pyoderma from private veterinary clinics in Buenos Aires area, were analyzed. Skin lesions swabs for both bacterial culture and mass spectrometry analysis were collected at the time of active pyoderma. Additionally, breed, sex, pyoderma classification, antimicrobial treatment and relapses of disease were recorded. Seventy-six percent of the studied animals received oral cephalexin after the clinical checkup, and within this percentage 31.6% also received other types of antimicrobial agents due to relapses. The remaining 24% had only antimicrobial treatment with lincomycin, minocycline and/or doxycycline. In sixty percent of the animals, pyoderma was related to allergy, which in turn was in concordance with relapses and was similar to the percentage of methicillin resistance (51%) of the different isolates of Staphylococcus sp. Eighty percent of the methicillin resistances were previously treated with cephalexin. Surprisingly, the highest percentages of resistance were to erythromycin, clindamycin (demonstrating constitutive MLSB phenotype), and sulfatrimethoprim.